0001387131-21-007179.txt : 20210706
0001387131-21-007179.hdr.sgml : 20210706
20210706163814
ACCESSION NUMBER: 0001387131-21-007179
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210702
FILED AS OF DATE: 20210706
DATE AS OF CHANGE: 20210706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40545
FILM NUMBER: 211074606
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CVRx, Inc.
CENTRAL INDEX KEY: 0001235912
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 9201 WEST BROADWAY AVENUE
STREET 2: SUITE 650
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55445
BUSINESS PHONE: 7634162850
MAIL ADDRESS:
STREET 1: 9201 WEST BROADWAY AVENUE
STREET 2: SUITE 650
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55445
FORMER COMPANY:
FORMER CONFORMED NAME: CVRX INC
DATE OF NAME CHANGE: 20030527
4
1
cvrx-form4_070221.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
X0306
4
2021-07-02
1
0001235912
CVRx, Inc.
CVRX
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
0
0
1
0
Common Stock
2021-07-02
4
C
0
1505
A
33316
I
See Footnote
Common Stock
2021-07-02
4
C
0
12979
A
46295
I
See Footnote
Common Stock
2021-07-02
4
C
0
14917
A
61212
I
See Footnote
Common Stock
2021-07-02
4
C
0
8380
A
69592
I
See Footnote
Common Stock
2021-07-02
4
C
0
27345
A
96937
I
See Footnote
Common Stock
2021-07-02
4
C
0
635646
A
732583
I
See Footnote
Common Stock
2021-07-02
4
P
0
275000
18
A
1007583
I
See Footnote
Series B-2 Preferred Stock
2021-07-02
4
C
0
59527
0
D
Common Stock
1505
0
I
See Footnote
Series C-2 Preferred Stock
2021-07-02
4
C
0
513312
0
D
Common Stock
12979
0
I
See Footnote
Series D-2 Preferred Stock
2021-07-02
4
C
0
589939
0
D
Common Stock
14917
0
I
See Footnote
Series E-2 Preferred Stock
2021-07-02
4
C
0
331399
0
D
Common Stock
8380
0
I
See Footnote
Series F-2 Preferred Stock
2021-07-02
4
C
0
1081434
0
D
Common Stock
27345
0
I
See Footnote
Series G Preferred Stock
2021-07-02
4
C
0
10055408
0
D
Common Stock
635646
0
I
See Footnote
Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.
The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.
/s/ Victoria Whyte
2021-07-06